Literature DB >> 30004792

Cancer immunology and radiobiology: Oliver Scott's struggle for the perfect tumour model in translational research.

Klaus-Rüdiger Trott1.   

Abstract

Oliver Scott is best known for his research into the role of tumour hypoxia in radiation oncology. Yet no less important were Oliver's activities in the development of concepts and methods for performing translational research on the effect of ionising radiation on tumour in experimental animals, stressing the importance of using strictly inbred animals for transplantation of tumours which had arisen in exactly the identical mouse strain. Otherwise residual immunity would lead to uncontrollable bias in the results of cure experiments, invalidating conclusions. These pioneering views are no less valid in today's cancer research.

Entities:  

Mesh:

Year:  2018        PMID: 30004792      PMCID: PMC6435059          DOI: 10.1259/bjr.20180188

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  6 in total

1.  Some aspects of the effect of ionizing radiation on tumors in experimental animals.

Authors:  O C SCOTT
Journal:  Adv Biol Med Phys       Date:  1958

2.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.

Authors:  L H GRAY; A D CONGER; M EBERT; S HORNSEY; O C SCOTT
Journal:  Br J Radiol       Date:  1953-12       Impact factor: 3.039

3.  The case of the impure mouse.

Authors:  O C Scott
Journal:  BJR Suppl       Date:  1992

Review 4.  Tumor transplantation and tumor immunity: a personal view.

Authors:  O C Scott
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

5.  The choice of experimental tumour systems.

Authors:  O C Scott
Journal:  Br J Cancer Suppl       Date:  1980-04

6.  An experimental method for comparing treatments of intact malignant tumours in animals and its application to the use of oxygen in radiotherapy.

Authors:  R H THOMLINSON
Journal:  Br J Cancer       Date:  1960-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.